Robert J Fontana

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1993754/publications.pdf

Version: 2024-02-01

241 papers

26,238 citations

71
h-index

158

g-index

255 all docs 255 docs citations

times ranked

255

19000 citing authors

#	Article	IF	Citations
1	A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology, 2003, 38, 518-526.	7.3	3,455
2	Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States. Annals of Internal Medicine, 2002, 137, 947.	3.9	1,856
3	Acetaminophen-induced acute liver failure: Results of a United States multicenter, prospective study. Hepatology, 2005, 42, 1364-1372.	7.3	1,688
4	Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States. Gastroenterology, 2008, 135, 1924-1934.e4.	1.3	748
5	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology, 2015, 149, 649-659.	1.3	725
6	Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology, 2015, 148, 1340-1352.e7.	1.3	646
7	ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. American Journal of Gastroenterology, 2014, 109, 950-966.	0.4	631
8	Intravenous N-Acetylcysteine Improves Transplant-Free Survival in Early Stage Non-Acetaminophen Acute Liver Failure. Gastroenterology, 2009, 137, 856-864.e1.	1.3	573
9	Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. Journal of Hepatology, 2005, 42, 218-224.	3.7	461
10	Drug-Induced Liver Injury Network (DILIN) Prospective Study. Drug Safety, 2009, 32, 55-68.	3.2	416
11	Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles. Gastroenterology, 2011, 141, 338-347.	1.3	412
12	Intensive care of patients with acute liver failure: Recommendations of the U.S. Acute Liver Failure Study Group. Critical Care Medicine, 2007, 35, 2498-2508.	0.9	408
13	Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or postâ€liver transplantation recurrence. Hepatology, 2016, 63, 1493-1505.	7.3	397
14	Virologic response and resistance to adefovir in patients with chronic hepatitis B. Journal of Hepatology, 2006, 44, 283-290.	3.7	337
15	Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology, 2014, 60, 1399-1408.	7.3	326
16	Hepatic histological findings in suspected drugâ€induced liver injury: Systematic evaluation and clinical associations. Hepatology, 2014, 59, 661-670.	7.3	322
17	Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation. Gastroenterology, 2015, 148, 108-117.	1.3	317
18	Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transplantation, 2005, 11, 1581-1589.	2.4	298

#	Article	IF	CITATIONS
19	NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States. Hepatology, 2002, 36, 1349-1354.	7.3	296
20	Causality assessment in drug-induced liver injury using a structured expert opinion process: Comparison to the Roussel-Uclaf causality assessment method. Hepatology, 2010, 51, 2117-2126.	7.3	295
21	Acute Hepatitis E Infection Accounts for Some Cases of Suspected Drug-Induced Liver Injury. Gastroenterology, 2011, 141, 1665-1672.e9.	1.3	294
22	Outcomes in Adults With Acute Liver Failure Between 1998 and 2013. Annals of Internal Medicine, 2016, 164, 724.	3.9	279
23	Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology, 2002, 123, 719-727.	1.3	266
24	Measurement of Serum Acetaminophen–Protein Adducts in Patients With Acute Liver Failure. Gastroenterology, 2006, 130, 687-694.	1.3	263
25	Autoimmune acute liver failure: Proposed clinical and histological criteria. Hepatology, 2011, 53, 517-526.	7.3	245
26	Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology, 2009, 49, S185-S195.	7.3	230
27	Mechanisms of drug-induced liver injury: from bedside to bench. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 202-211.	17.8	225
28	Pathogenesis of Idiosyncratic Drug-Induced Liver Injury and Clinical Perspectives. Gastroenterology, 2014, 146, 914-928.e1.	1.3	222
29	Polymerase Î ³ Gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology, 2010, 52, 1791-1796.	7.3	219
30	Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology, 2015, 61, 1485-1494.	7.3	206
31	Acute Liver Failure Including Acetaminophen Overdose. Medical Clinics of North America, 2008, 92, 761-794.	2.5	201
32	Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network. Hepatology, 2014, 60, 679-686.	7.3	200
33	Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. Hepatology, 2006, 44, 1589-1597.	7.3	189
34	Idiosyncratic Drug-Induced Liver Injury Is Associated With Substantial Morbidity and Mortality Within 6 Months From Onset. Gastroenterology, 2014, 147, 96-108.e4.	1.3	188
35	Liver Injury From Tumor Necrosis Factor-α Antagonists: Analysis of Thirty-four Cases. Clinical Gastroenterology and Hepatology, 2013, 11, 558-564.e3.	4.4	187
36	Association of Liver Injury From Specific Drugs, or Groups ofÂDrugs, With Polymorphisms in HLA and Other Genes in aÂGenome-Wide Association Study. Gastroenterology, 2017, 152, 1078-1089.	1.3	174

#	Article	IF	CITATIONS
37	Candidate biomarkers for the diagnosis and prognosis of drugâ€induced liver injury: An international collaborative effort. Hepatology, 2019, 69, 760-773.	7.3	166
38	Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology, 2008, 48, 1175-1183.	7.3	158
39	Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology, 2008, 47, 789-798.	7.3	155
40	Iron reduction before and during interferon therapy of chronic hepatitisÂC: Results of a multicenter, randomized, controlled trial. Hepatology, 2000, 31, 730-736.	7.3	154
41	The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology, 2018, 68, 872-882.	7.3	154
42	Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: A safe and effective bridge to liver transplantation. Liver Transplantation, 2002, 8, 1165-1174.	2.4	151
43	Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. Gastroenterology, 1999, 117, 89-98.	1.3	131
44	Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. Journal of Hepatology, 2007, 46, 420-431.	3.7	125
45	Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transplantation, 2002, 8, 433-439.	2.4	119
46	Noninvasive monitoring of patients with chronic hepatitis C. Hepatology, 2002, 36, S57-S64.	7.3	118
47	Noninvasive monitoring of patients with chronic hepatitis C. Hepatology, 2002, 36, s57-s64.	7.3	114
48	Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. Journal of Hepatology, 2002, 36, 401-407.	3.7	109
49	Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenetics and Genomics, 2012, 22, 784-795.	1.5	108
50	United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts. Toxicology Reports, 2020, 7, 386-402.	3.3	108
51	Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology, 2017, 65, 1267-1277.	7.3	105
52	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. Gastroenterology, 2019, 156, 1707-1716.e2.	1.3	97
53	Death and liver transplantation within 2 years of onset of drugâ€induced liver injury. Hepatology, 2017, 66, 1275-1285.	7.3	96
54	Clinical and Histologic Features of Azithromycin-Induced Liver Injury. Clinical Gastroenterology and Hepatology, 2015, 13, 369-376.e3.	4.4	95

#	Article	IF	Citations
55	The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointestinal Endoscopy, 2006, 64, 855-864.	1.0	94
56	Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. American Journal of Gastroenterology, 2001, 96, 2737-2744.	0.4	93
57	Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transplantation, 2007, 13, 1100-1108.	2.4	92
58	Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut, 2010, 59, 1401-1409.	12.1	92
59	Amoxicillin–Clavulanate-Induced Liver Injury. Digestive Diseases and Sciences, 2016, 61, 2406-2416.	2.3	92
60	Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. American Journal of Gastroenterology, 2001, 96, 170-178.	0.4	89
61	Bleeding complications in acute liver failure. Hepatology, 2018, 67, 1931-1942.	7.3	86
62	Characteristics of Idiosyncratic Drugâ€induced Liver Injury in Children. Journal of Pediatric Gastroenterology and Nutrition, 2011, 53, 182-189.	1.8	85
63	Persistent Liver Biochemistry Abnormalities Are More Common in Older Patients and those With Cholestatic Drug Induced Liver Injury. American Journal of Gastroenterology, 2015, 110, 1450-1459.	0.4	85
64	Roles of Iron and HFE Mutations on Severity and Response to Therapy During Retreatment of Advanced Chronic Hepatitis C. Gastroenterology, 2006, 131, 1440-1451.	1.3	83
65	Detection and diagnosis of herpes simplex virus infection in adults with acute liver failure. Liver Transplantation, 2008, 14, 1498-1504.	2.4	83
66	Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. Liver Transplantation, 1999, 5, 480-484.	1.8	81
67	Acute Liver Failure Due To Amoxicillin and Amoxicillin/Clavulanate. Digestive Diseases and Sciences, 2005, 50, 1785-1790.	2.3	81
68	Determinants of outcome among patients with acute liver failure listed for liver transplantation in the United States. Liver Transplantation, 2016, 22, 505-515.	2.4	79
69	Epstein–Barr Virus (EBV) Related Acute Liver Failure: A Case Series from the US Acute Liver Failure Study Group. Digestive Diseases and Sciences, 2014, 59, 1630-1637.	2.3	75
70	Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. Journal of Hepatology, 2005, 43, 614-622.	3.7	74
71	Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transplantation, 2016, 22, 446-458.	2.4	73
72	Misconceptions, preferences and barriers to alcohol use disorder treatment in alcohol-related cirrhosis. Journal of Substance Abuse Treatment, 2018, 91, 20-27.	2.8	73

#	Article	IF	CITATIONS
73	Transjugular intrahepatic portosystemic shunts and liver transplantation in patients with refractory hepatic hydrothorax. Liver Transplantation, 1998, 4, 416-423.	1.8	71
74	Profiles of Serum Cytokines in Acute Drug-Induced Liver Injury and Their Prognostic Significance. PLoS ONE, 2013, 8, e81974.	2.5	71
75	Searching for a Needle in a Haystack: Use of ICD-9-CM Codes in Drug-Induced Liver Injury. American Journal of Gastroenterology, 2007, 102, 2437-2443.	0.4	67
76	Liver injury from nonsteroidal antiâ€inflammatory drugs in the United States. Liver International, 2016, 36, 603-609.	3.9	67
77	Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transplantation, 2012, 18, 1053-1059.	2.4	66
78	Clinical Features, Diagnosis, and Natural History of Drug-Induced Liver Injury. Seminars in Liver Disease, 2014, 34, 134-144.	3.6	63
79	Neuropsychiatric Toxicity of Antiviral Treatment in Chronic Hepatitis C. Digestive Diseases, 2000, 18, 107-116.	1.9	61
80	A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transplantation, 2001, 7, 504-510.	2.4	61
81	Portal Hypertensive Gastropathy in Chronic Hepatitis C Patients with Bridging Fibrosis and Compensated Cirrhosis: Results from the HALT-C Trial. American Journal of Gastroenterology, 2006, 101, 983-992.	0.4	61
82	Acute Liver Failure Due to Drugs. Seminars in Liver Disease, 2008, 28, 175-187.	3.6	61
83	Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy. Alimentary Pharmacology and Therapeutics, 2019, 50, 800-808.	3.7	60
84	Twoâ€year outcomes in initial survivors with acute liver failure: results from a prospective, multicentre study. Liver International, 2015, 35, 370-380.	3.9	59
85	A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus–related cirrhosis. Liver Transplantation, 2003, 9, 49-56.	2.4	58
86	Clinical significance of hepatitis B virus genotypes, variants, and mutants. Clinics in Liver Disease, 2004, 8, 321-352.	2.1	58
87	An Immunoassay to Rapidly Measure Acetaminophen ProteinÂAdducts Accurately Identifies Patients With Acute LiverÂInjury or Failure. Clinical Gastroenterology and Hepatology, 2017, 15, 555-562.e3.	4.4	58
88	Prospective Analysis of Depression During Peginterferon and Ribavirin Therapy of Chronic Hepatitis C. American Journal of Gastroenterology, 2009, 104, 2949-295.	0.4	57
89	Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. Journal of Hepatology, 2014, 60, 872-884.	3.7	56
90	Gender Disparities in Alcohol Use Disorder Treatment Among Privately Insured Patients with Alcoholâ€Associated Cirrhosis. Alcoholism: Clinical and Experimental Research, 2019, 43, 334-341.	2.4	56

#	Article	IF	CITATIONS
91	Idiosyncratic Drug Induced Liver Injury in African–Americans Is Associated With Greater Morbidity and Mortality Compared to Caucasians. American Journal of Gastroenterology, 2017, 112, 1382-1388.	0.4	55
92	Noninvasive Intracranial Pressure Assessment in Acute Liver Failure. Neurocritical Care, 2018, 29, 280-290.	2.4	55
93	Multicenter Study to Transplant Hepatitis C–Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. Journal of the American Society of Nephrology: JASN, 2020, 31, 2678-2687.	6.1	55
94	Stem cell–derived models to improve mechanistic understanding and prediction of human drugâ€induced liver injury. Hepatology, 2017, 65, 710-721.	7.3	54
95	Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology, 2006, 44, 925-935.	7.3	53
96	The diagnosis and management of idiosyncratic drugâ€induced liver injury. Liver International, 2019, 39, 31-41.	3.9	53
97	HLAâ€B*35:01 and Green Tea–Induced Liver Injury. Hepatology, 2021, 73, 2484-2493.	7. 3	53
98	Short and Long-Term Outcomes in Patients with Acute Liver Failure Due to Ischemic Hepatitis. Digestive Diseases and Sciences, 2012, 57, 777-785.	2.3	52
99	A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma. Oncologist, 2021, 26, 133-138.	3.7	52
100	A revised electronic version of RUCAM for the diagnosis of DILI. Hepatology, 2022, 76, 18-31.	7.3	52
101	Identification and Characterization of Fenofibrate-Induced Liver Injury. Digestive Diseases and Sciences, 2017, 62, 3596-3604.	2.3	49
102	Profiles of mi <scp>RNA</scp> s in serum in severe acute drug induced liver injury and their prognostic significance. Liver International, 2017, 37, 757-764.	3.9	49
103	Management of Patients with Decompensated HBV Cirrhosis. Seminars in Liver Disease, 2003, 23, 089-100.	3.6	48
104	Heat stroke leading to acute liver injury & Description of the Acute Liver Failure Study Group. Liver International, 2017, 37, 509-513.	3.9	48
105	Acute Liver Injury due to Flavocoxid (Limbrel), a Medical Food for Osteoarthritis. Annals of Internal Medicine, 2012, 156, 857.	3.9	47
106	Hepatitis B infection in patients with acute liver failure in the United States. Hepatology, 2001, 33, 972-976.	7.3	43
107	Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors. Alimentary Pharmacology and Therapeutics, 2019, 49, 1195-1204.	3.7	43
108	Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprimâ€Sulfamethoxazole Induced Liver Injury. Hepatology, 2021, 73, 268-281.	7.3	43

#	Article	lF	Citations
109	Serum Fibrosis Marker Levels Decrease After Successful Antiviral Treatment in Chronic Hepatitis C Patients With Advanced Fibrosis. Clinical Gastroenterology and Hepatology, 2009, 7, 219-226.	4.4	42
110	Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity. Clinical Gastroenterology and Hepatology, 2015, 13, 1676-1682.e1.	4.4	42
111	Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepatology, 2007, 45, 1154-1163.	7.3	41
112	Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drugâ€Induced Liver Injury Network (<scp>DILIN</scp>). Liver International, 2015, 35, 1623-1632.	3.9	41
113	Emotional Distress During Interferon-α-2B and Ribavirin Treatment of Chronic Hepatitis C. Psychosomatics, 2002, 43, 378-385.	2.5	40
114	Changes in Mood States and Biomarkers During Peginterferon and Ribavirin Treatment of Chronic Hepatitis C. American Journal of Gastroenterology, 2008, 103, 2766-2775.	0.4	40
115	Constitutive release of CPS1 in bile and its role as a protective cytokine during acute liver injury. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9125-9134.	7.1	39
116	Factors That Determine the Development and Progression of Gastroesophageal Varices in Patients With Chronic Hepatitis C. Gastroenterology, 2010, 138, 2321-2331.e2.	1.3	38
117	Fibrosis Progression in African Americans and Caucasian Americans With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2008, 6, 1403-1411.	4.4	37
118	Severe Acute Hepatocellular Injury Attributed to OxyELITE Pro: A Case Series. Digestive Diseases and Sciences, 2016, 61, 2741-2748.	2.3	37
119	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. Journal of Autoimmunity, 2020, 114, 102514.	6.5	37
120	Endoscopic Transpapillary Gallbladder Stent Placement Is Safe and Effective in High-Risk Patients Without Cirrhosis. Digestive Diseases and Sciences, 2015, 60, 2516-2522.	2.3	36
121	Acute Liver Failure (ALF) in Pregnancy: How Much Is Pregnancy Related?. Hepatology, 2020, 72, 1366-1377.	7.3	35
122	Cytokine gene polymorphisms in chronic hepatitis B: a step up the immunology ladder. American Journal of Gastroenterology, 2003, 98, 6-8.	0.4	33
123	Carbamoyl phosphate synthetase-1 is a rapid turnover biomarker in mouse and human acute liver injury. American Journal of Physiology - Renal Physiology, 2014, 307, G355-G364.	3.4	33
124	Relationship Between Characteristics of Medications and Drug-Induced Liver Disease Phenotype and Outcome. Clinical Gastroenterology and Hepatology, 2014, 12, 1550-1555.	4.4	32
125	HBV-Associated Acute Liver Failure After Immunosuppression and Risk of Death. Clinical Gastroenterology and Hepatology, 2017, 15, 113-122.	4.4	32
126	Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response. Journal of Immunotoxicology, 2017, 14, 31-38.	1.7	32

#	Article	IF	CITATIONS
127	Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis. Hepatology International, 2019, 13, 641-648.	4.2	32
128	Vemurafenibâ€induced granulomatous hepatitis. Hepatology, 2017, 65, 745-748.	7.3	31
129	Safety, tolerability, and pharmacokinetics of lâ€ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia. Hepatology, 2018, 67, 1003-1013.	7.3	31
130	Immune thrombocytopenic purpura following liver transplantation: A case series and review of the literature. Liver Transplantation, 2006, 12, 781-791.	2.4	30
131	Quality of life is significantly impaired in long-term survivors of acute liver failure and particularly in acetaminophen-overdose patients. Liver Transplantation, 2013, 19, 991-1000.	2.4	30
132	Protocol based invasive intracranial pressure monitoring in acute liver failure: feasibility, safety and impact on management. Critical Care, 2017, 21, 178.	5.8	30
133	Cytokine profiles in acute liver injury—Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group. PLoS ONE, 2018, 13, e0206389.	2.5	29
134	Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. Clinical Gastroenterology and Hepatology, 2019, 17, 2541-2551.e2.	4.4	28
135	The Contents of Herbal and Dietary Supplements Implicated in Liver Injury in the United States Are Frequently Mislabeled. Hepatology Communications, 2019, 3, 792-794.	4.3	27
136	Presentation and Outcomes with Clinically Apparent Interferon Beta Hepatotoxicity. Digestive Diseases and Sciences, 2013, 58, 1766-1775.	2.3	26
137	Gender Disparities in Patients With Alcoholic Liver Disease Evaluated for Liver Transplantation. Transplantation, 2020, 104, 293-298.	1.0	25
138	A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: Case report. Journal of Medical Case Reports, 2007, 1, 88.	0.8	24
139	Outcomes of Patients With Chronic Hepatitis B Who Do Not Meet Criteria for Antiviral Treatment at Presentation. Clinical Gastroenterology and Hepatology, 2015, 13, 193-201.e1.	4.4	24
140	Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. Hepatology, 2021, 73, 2124-2140.	7.3	23
141	Clinical Relevance of Cognitive Scores in Hepatitis C Patients with Advanced Fibrosis. Journal of Clinical and Experimental Neuropsychology, 2006, 28, 1346-1361.	1.3	22
142	Bariatric surgery and the risk of alcoholâ€related cirrhosis and alcohol misuse. Liver International, 2021, 41, 1012-1019.	3.9	22
143	<scp>YKL</scp> â€40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver International, 2012, 32, 665-674.	3.9	21
144	Fatigue in Patients with Chronic Hepatitis B Living in North America: Results from the Hepatitis B Research Network (HBRN). Digestive Diseases and Sciences, 2016, 61, 1186-1196.	2.3	21

#	Article	IF	CITATIONS
145	Antimicrobials and Antiepileptics Are the Leading Causes of Idiosyncratic Drugâ€induced Liver Injury in American Children. Journal of Pediatric Gastroenterology and Nutrition, 2019, 69, 152-159.	1.8	21
146	Computed tomography appearances of hypervascular hepatic tumors after percutaneous radiofrequency ablation therapy. Current Problems in Diagnostic Radiology, 2002, 31, 105-111.	1.4	20
147	Transpapillary Gallbladder Stents Can Stabilize or Improve Decompensated Cirrhosis in Patients Awaiting Liver Transplantation. Journal of Clinical Gastroenterology, 2015, 49, 771-777.	2.2	20
148	Coagulopathy, Bleeding Events, and Outcome According to Rotational Thromboelastometry in Patients With Acute Liver Injury/Failure. Hepatology, 2021, 74, 937-949.	7.3	20
149	Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. Clinical Gastroenterology and Hepatology, 2004, 2, 183-197.	4.4	19
150	Entecavir in decompensated HBV cirrhosis: The future is looking brighter. Journal of Hepatology, 2010, 52, 147-149.	3.7	19
151	Liver injury associated with kratom, a popular opioid-like product: Experience from the U.S. drug induced liver injury network and a review of the literature. Drug and Alcohol Dependence, 2021, 218, 108426.	3.2	19
152	Guillainâ€Barré Syndrome After COVIDâ€19 mRNA Vaccination in a Liver Transplantation Recipient With Favorable Treatment Response. Liver Transplantation, 2022, 28, 134-137.	2.4	19
153	Risk of Liver Injury Associated with Green Tea Extract in SLIMQUICK® Weight Loss Products: Results from the DILIN Prospective Study. Drug Safety, 2016, 39, 749-754.	3.2	18
154	Associations of gender and a proxy of female menopausal status with histological features of drugâ€induced liver injury. Liver International, 2017, 37, 1723-1730.	3.9	18
155	Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury. BMC Medicine, 2015, 13, 196.	5 . 5	17
156	Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis B and Low-Level Viremia. American Journal of Gastroenterology, 2019, 114, 1753-1763.	0.4	17
157	Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles. Liver International, 2021, 41, 1884-1893.	3.9	17
158	Development and Progression of Portal Hypertensive Gastropathy in Patients With Chronic Hepatitis C. American Journal of Gastroenterology, 2011, 106, 884-893.	0.4	16
159	Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study. Journal of Hepatology, 2022, 76, 832-840.	3.7	16
160	A Text Searching Tool to Identify Patients with Idiosyncratic Drug-Induced Liver Injury. Digestive Diseases and Sciences, 2017, 62, 615-625.	2.3	15
161	Sclerosing Cholangitis–Like Changes on Magnetic Resonance Cholangiography in Patients With Drug Induced Liver Injury. Clinical Gastroenterology and Hepatology, 2019, 17, 789-790.	4.4	15
162	The patient's perspective in hepatitis C. Hepatology, 2004, 39, 903-905.	7.3	14

#	Article	IF	CITATIONS
163	Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. Transplant International, 2017, 30, 196-208.	1.6	14
164	Acute liver failure. Current Opinion in Gastroenterology, 2001, 17, 291-298.	2.3	13
165	Outcome of liver transplantation for hepatitis B: Report of a single center's experience. Liver Transplantation, 2001, 7, 724-731.	2.4	13
166	Cognitive Function Does Not Worsen During Long-Term Low-Dose Peginterferon Therapy in Patients With Chronic Hepatitis C. American Journal of Gastroenterology, 2010, 105, 1551-1560.	0.4	13
167	Immunological dysfunction during or after antiviral therapy for recurrent hepatitis C reduces graft survival. Hepatology International, 2013, 7, 990-999.	4.2	13
168	Vedolizumab is safe and effective in moderateâ€toâ€severe inflammatory bowel disease following liver transplantation. Liver Transplantation, 2017, 23, 968-971.	2.4	13
169	Garcinia cambogia, Either Alone or in Combination With Green Tea, Causes Moderate to Severe Liver Injury. Clinical Gastroenterology and Hepatology, 2022, 20, e1416-e1425.	4.4	13
170	Incidence and prediction of HBsAg seroclearance in a prospective multiâ€ethnic HBeAgâ€negative chronic hepatitis B cohort. Hepatology, 2022, 75, 709-723.	7.3	13
171	The Role of Optimism/Pessimism in HRQOL in Chronic Hepatitis C Patients. Journal of Clinical Psychology in Medical Settings, 2003, 10, 41-49.	1.4	12
172	Optimizing Outcomes in Hepatitis C: Is Treatment Beyond 48 Weeks Ever Justified?. Gastroenterology, 2006, 130, 1357-1362.	1.3	12
173	Acetaminophen overdose: What practitioners need to know. Clinical Liver Disease, 2014, 4, 17-21.	2.1	12
174	One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial. Kidney International Reports, 2022, 7, 241-250.	0.8	12
175	Management of Drug-Resistant Chronic Hepatitis B. Clinics in Liver Disease, 2006, 10, 275-302.	2.1	11
176	Utility of a Computerized ICD-10 Algorithm to Identify Idiosyncratic Drug-Induced Liver Injury Cases in the Electronic Medical Record. Drug Safety, 2020, 43, 371-377.	3.2	11
177	Clinical and Neurologic Outcomes in Acetaminophen-Induced Acute Liver Failure: A 21-Year Multicenter Cohort Study. Clinical Gastroenterology and Hepatology, 2021, 19, 2615-2625.e3.	4.4	11
178	Patientâ€reported outcomes in a large North American cohort living with chronic hepatitis B virus: a crossâ€sectional analysis. Alimentary Pharmacology and Therapeutics, 2020, 51, 457-468.	3.7	11
179	Secular Trends in Severe Idiosyncratic Drug-Induced Liver Injury in North America: An Update From the Acute Liver Failure Study Group Registry. American Journal of Gastroenterology, 2022, 117, 617-626.	0.4	11
180	Association of Variants of Arginine Vasopressin and ArginineÂVasopressin Receptor 1A With Severe AcetaminophenÂLiver Injury. Cellular and Molecular Gastroenterology and Hepatology, 2017, 3, 500-505.	4.5	10

#	Article	IF	CITATIONS
181	Importance of Hepatitis C Virus RNA Testing in Patients with Suspected Drug-Induced Liver Injury. Digestive Diseases and Sciences, 2019, 64, 2645-2652.	2.3	10
182	Prophylactic Anticoagulation in Cirrhotics: A Paradox for Prime Time?. Gastroenterology, 2012, 143, 1138-1141.	1.3	9
183	Liver safety assessment in clinical trials of new agents for chronic hepatitis B. Journal of Viral Hepatitis, 2020, 27, 96-109.	2.0	9
184	Marijuana use among adult liver transplant candidates and recipients. Clinical Transplantation, 2021, 35, e14312.	1.6	9
185	Prognostic Value of the 13Câ€Methacetin Breath Test in Adults with Acute Liver Failure and Nonâ€acetaminophen Acute Liver Injury. Hepatology, 2021, 74, 961-972.	7.3	9
186	Celecoxib-induced Liver Injury. Journal of Clinical Gastroenterology, 2018, 52, 114-122.	2.2	8
187	Results of a Prospective, Randomized, Controlled Trial. Journal of Clinical Gastroenterology, 2002, 34, 177-182.	2.2	7
188	Nonresponders to hepatitis C virus antiviral therapy: pegylated interferons and beyond. Gastroenterology Clinics of North America, 2004, 33, 527-547.	2.2	7
189	Efficacy and Safety of 8ÂWeeks of Glecaprevir/Pibrentasvir in Treatment-NaÃ⁻ve, HCV-Infected Patients with APRIâ€‰â‰æ€‰1 in a Single-Arm, Open-Label, Multicenter Study. Advances in Therapy, 2019, 36, 3458-34	% ?	7
190	Role of Hepatitis E Virus Infection in North American Patients With Severe Acute Liver Injury. Clinical and Translational Gastroenterology, 2020, 11, e00273.	2.5	6
191	Potential Treatments for SARSâ€CoVâ€⊋ Infection. Clinical Liver Disease, 2020, 15, 181-186.	2.1	6
192	The Utility of Noninvasive PET/CT Myocardial Perfusion Imaging in Adult Liver Transplant Candidates. Transplantation Direct, 2022, 8, e1311.	1.6	6
193	CAQ Corner: Acute liver failure management and liver transplantation. Liver Transplantation, 2022, 28, 1664-1673.	2.4	6
194	Are we ready for marginal hepatitis B core antibody-positive living liver donors?. Liver Transplantation, 2003, 9, 833-836.	2.4	5
195	Renal Transplantation in HBsAg+ Patients. Journal of Clinical Gastroenterology, 2003, 37, 9-11.	2.2	5
196	Prevalence and Impact of Hepatitis E Virus Infection Among Persons With Chronic Hepatitis B Living in the US and Canada. Open Forum Infectious Diseases, 2019, 6, ofz175.	0.9	5
197	Reply:. Hepatology, 2005, 42, 739-740.	7.3	4
198	No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C. Journal of Affective Disorders, 2011, 129, 205-212.	4.1	4

#	Article	IF	Citations
199	Managing drug-drug interactions with boceprevir and telaprevir. Clinical Liver Disease, 2012, 1, 36-40.	2.1	4
200	Is Making a Prognosis for Patients With Drug-induced Liver Injury Putting the Cart Before the Horse?. Clinical Gastroenterology and Hepatology, 2015, 13, 2369-2371.	4.4	4
201	Quality of care metrics in chronic hepatitis B. Hepatology, 2016, 63, 1755-1758.	7.3	4
202	Temporal Changes in the Modes of Hepatitis C Virus Transmission in the USA and Northern China. Digestive Diseases and Sciences, 2017, 62, 2141-2149.	2.3	4
203	Liver Injury Associated with Sporting Activities. Seminars in Liver Disease, 2018, 38, 357-365.	3.6	4
204	Impact of a Prohibitive Versus Restrictive Tobacco Policy on Liver Transplant Candidate Outcomes. Liver Transplantation, 2019, 25, 1165-1176.	2.4	4
205	Comparison of clinical outcomes and impact of SVR in American and Chinese patients with chronic hepatitis C. JHEP Reports, 2020, 2, 100136.	4.9	4
206	With Alcohol as the Fuel, COVID Is the Match: Liver Transplantation for Alcoholâ€Associated Liver Disease Is Increasing in the United States. Hepatology, 2021, 74, 2948-2951.	7.3	4
207	Acute Liver Failure in the United States. Annals of Internal Medicine, 2003, 139, 1045.	3.9	4
208	Impact of Prior Drug Allergies on the Risk, Clinical Features, and Outcomes of Idiosyncratic Drug-Induced Liver Injury in Adults. Digestive Diseases and Sciences, 2022, 67, 5262-5271.	2.3	4
209	Infrequent liver injury from cemiplimab in patients with advanced cutaneous squamous cell carcinoma. Immunotherapy, 2022, 14, 409-418.	2.0	4
210	Combination of HBIG and lamivudine-resistant mutations: A formula for trouble?. Liver Transplantation, 2002, 8, 1082-1084.	2.4	3
211	Management of Decompensated HBV Cirrhosis: Lamivudine and Beyond. American Journal of Gastroenterology, 2004, 99, 64-67.	0.4	3
212	Valganciclovir for cytomegalovirus prophylaxis in liver transplant recipients. Liver Transplantation, 2006, 12, 1022-1023.	2.4	3
213	Should aciclovir be given to all patients presenting with acute liver failure of unknown etiology?. Nature Reviews Gastroenterology & Hepatology, 2008, 5, 298-299.	1.7	3
214	Practical Teaching Cases: A New Section for Trainees and Young Gls. Gastroenterology, 2015, 149, 266.	1.3	3
215	Severe Acute Hepatitis Attributed to the Herbal and Dietary Supplement OxyELITE Pro. Clinical Liver Disease, 2019, 14, 45-48.	2.1	3
216	Incidence and Sequelae of Liver Injury Among Children Treated for Solid Tumors. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, 197-202.	1.8	3

#	Article	IF	Citations
217	Role of Hepatitis C Infection in Acute Liver Injury/Acute Liver Failure in North America. Digestive Diseases and Sciences, 2023, 68, 304-311.	2.3	3
218	Assessment of the Newly Diagnosed Patient with Chronic Hepatitis B Virus Infection. American Journal of Medicine, 2008, 121, i-OBC.	1.5	2
219	Making the World a Safer Place. Seminars in Liver Disease, 2009, 29, 335-336.	3.6	2
220	Combining K-72 Hepatic Failure with 15 Individual T-Codes to Identify Patients with Idiosyncratic Drug-Induced Liver Injury in the Electronic Medical Record. Digestive Diseases and Sciences, 2022, 67, 4243-4249.	2.3	2
221	The Role of Tissue Biopsy in the Management of Immune Checkpoint Inhibitor Toxicity. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 417-425.	4.9	2
222	Reply:. Hepatology, 2006, 43, 882-882.	7.3	1
223	Reply:. Hepatology, 2008, 48, 689-690.	7.3	1
224	Approach to the Patient with Acute Liver Failure. , 0, , 492-515.		1
225	Evaluation of the patient with chronic hepatitis B. Clinical Liver Disease, 2013, 2, 1-4.	2.1	1
226	New Onset Bloody Diarrhea in a Liver Transplant Recipient. Gastroenterology, 2015, 149, 300-301.	1.3	1
227	Hepatitis E: Emerging Pathogen or Domestic Bystander?. Clinical Gastroenterology and Hepatology, 2015, 13, 1843-1845.	4.4	1
228	A Decline in Status 1 Listings: The Impact of Etiology and Medical Management of Acute Liver Failure. Liver Transplantation, $2019, 25, 1605-1608$.	2.4	1
229	Outcomes in Living Liver Donor "Heroes―After the Spotlight Fades. Liver Transplantation, 2019, 25, 685-687.	2.4	1
230	Author's Response to Letter to the Editor: Noninvasive Intracranial Pressure Assessment in Acute Liver Failure. Neurocritical Care, 2019, 30, 497-497.	2.4	1
231	Liver disease symptoms are associated with higher risk of adverse clinical outcomes: A longitudinal study of North American adults with chronic Hepatitis B. GastroHep, 2021, 3, 196-208.	0.6	1
232	Are herbals more hepatotoxic than prescription medications?. Hepatology International, 2021, 15, 1301-1304.	4.2	1
233	Drug-Induced Liver Injury Research Networks. , 2013, , 713-723.		0
234	Reply. Gastroenterology, 2015, 149, 1990-1991.	1.3	0

ROBERT J FONTANA

#	Article	IF	CITATIONS
235	Response to Collyer et al American Journal of Gastroenterology, 2016, 111, 297-298.	0.4	O
236	Introducing the AASLD president: Anna S.F. Lok. Hepatology, 2017, 65, 1084-1087.	7.3	0
237	Reply. Hepatology, 2017, 65, 389-390.	7.3	0
238	Re: Distinguishing Between Sex and Gender Is Critical for Research in Transplantation. Transplantation, 2020, 104, e58-e58.	1.0	0
239	Management of Acute Liver Failure. , 2017, , 551-560.		0
240	Management of Acute Liver Failure. , 2020, , 523-531.		0
241	Approach to the Patient with Acute Liver Failure. , 0, , 114-135.		0